Adaptive treatment before surgery for HER2-positive breast cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how the tumor responds, aiming to improve outcomes while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have early or locally advanced breast cancer that can be removed with surgery, with a tumor larger than 2 cm.
- Your cancer is HER2-positive (confirmed by a test).
- You have not had prior chemotherapy, hormone therapy, or HER2-targeted therapy for this cancer.
- You are generally healthy enough to undergo treatment and surgery.
- You agree to provide tumor tissue and blood samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
Hear when a new Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.